

Givastomig Biosimilar - Research Grade

Product Code: ICH6024

More Information

Species Reactivity: Human

Target: TNFRSF9 + CLDN18

Concentration: 5mg/ml

Isotype: Human IgG1(N297A)-kappa-(SCFV-Lambda)2

product name H2: Givastomig Biosimilar - Research Grade

Sequence: <https://www.imgt.org/mAb-DB/>

Buffer: ICH3002

UniProt: Q07011;P56856

Shipping Conditions: Blue ice

background: Bridging T-cell co-stimulation with tumour-antigen targeting, dual engagement of 4-1BB (TNFRSF9) and claudin-18 (CLDN18) is an emerging approach for conditional immune activation in oncology research. This research-grade bispecific antibody is an unconjugated, non-therapeutic analog of givastomig, designed to bind TNFRSF9 and CLDN18 for preclinical study of localized T-cell co-stimulation. Validated for functional assays and supplied for research use only (RUO), it is produced to in vivo grade standards as an ultra-pure, low-endotoxin preparation. Available in scalable milligram (mg) to gram (g) quantities, it supports in vitro screening, in vivo tumour models and mechanistic studies in high-throughput and bulk laboratories.

Purification Method: This monoclonal antibody was purified using IEC

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity: >90% by SDS-PAGE



Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.